Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.54 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3187395 | 0.84 | S1PR1 (0.50) | CA2CAMK2ACA1HIF1ACYP1A1 | |
| SCHEMBL156664 | 0.83 | MEN1 (0.56) | ALDH1A1 | |
| SCHEMBL1202552 | 0.82 | HTT (0.61) | ALDH1A1 | |
| SCHEMBL5939339 | 0.82 | FFAR1 (0.56) | ALDH1A1 | |
| SCHEMBL18459808 | 0.82 | KDM4E (0.52) | CA2CA1HIF1AALDH1A1 | |
| SCHEMBL23105604 | 0.82 | LMNA (0.52) | CA2CA1ALDH1A1 | |
| SCHEMBL8991901 | 0.82 | ALDH1A1 (0.65) | ALDH1A1 | |
| SCHEMBL841278 | 0.82 | L3MBTL1 (0.50) | CA2CA1 | |
| SCHEMBL11273783 | 0.82 | CA2 (0.55) | CA2CAMK2ACA1HIF1A | |
| SCHEMBL18487413 | 0.82 | FOLH1 (0.49) | CA2CA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328877-B1 | PEPTOID | THE UNIV OF DURHAM (GB) | 2022-08-24 | — | — | EP | claimed |
| US-20180201647-A1 | Peptoid | THE UNIVERSITY OF DURHAM (GB) | 2018-07-19 | — | — | US | claimed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | claimed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | claimed |
| US-9512139-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2016-12-06 | — | — | US | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| EP-2477643-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | Novo Nordisk A/S (DK) | 2012-07-25 | — | — | EP | claimed |
| WO-2011058165-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2011-05-19 | — | — | WO | claimed |
| WO-2011033068-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2011-03-24 | — | — | WO | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
| US-20080233137-A1 | Compounds that Block the C5a Receptor and Their Use in Therapy | ALLIGATOR BIOSCIENCE AB (SE) | 2008-09-25 | — | — | US | claimed |
| EP-1737886-A2 | COMPOUNDS THAT BLOCK THE C5A RECEPTOR AND THEIR USE IN THERAPY | Alligator Bioscience AB (publ) (SE) | 2007-01-03 | — | — | EP | claimed |
| WO-2005100385-A2 | COMPOUNDS THAT BLOCK THE C5A RECEPTOR AND THEIR USE IN THERAPY | ALLIGATOR BIOSCIENCE AB (PUBL) (SE) | 2005-10-27 | — | — | WO | claimed |
| EP-1586583-A2 | Compounds that block C5a complement receptor and their use in therapy | Alligator Bioscience AB (publ) (SE) | 2005-10-19 | — | — | EP | claimed |
| WO-2003006048-A1 | COMBINATION OF CHIPS (CHEMOTAXIS INHIBITING PROTEIN FROM STAPHYLOCOCCUS AUREUS)-BASED COMPOUNDS | JARI PHARMACEUTICALS B.V. (NL) | 2003-01-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | CA2 3971/4885CAMK2A 3530/4885CA1 4709/4885 |
| US-20180201647-A1 | Peptoid | ARG1, ARGLU1, QPCT | CA2 2443/4885CAMK2A 3646/4885CA1 3709/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | CA2 1290/4885CAMK2A 1167/4885CA1 1457/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | CA2 1290/4885CAMK2A 1167/4885CA1 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.